Ana S. C. Valdeira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ana S. C. Valdeira has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jorge António Ribeiro Salvador
Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal
4 shared publications - Ana Sofia Leal
Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
2 shared publications - Bruno M. F. Gonçalves
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
2 shared publications - Daniela P. S. Alho
Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal
2 shared publications - Kirk R. Gustafson
Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702-1201, United States
2 shared publications - Vanessa I S Mendes
Center for Neuroscience and Cell Biology, Coimbra, Portugal; CHEM4PHARMA, Biocant - Parque Tecnológico de Cantanhede, Núcleo 4, Lote 14, 3060-197, Cantanhede, Portugal
2 shared publications
Latest Publications
- 25 July 2019
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 82 (8) , 2094-2105
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation
A series of novel madecassic acid (1) derivatives was synthesized, and their cytotoxicity was evaluated against the NCI-60 panel of cancer cell lines. Several analogues exhibited broad-spectrum cytotoxic activities over all nine tumor types represented in the panel, with more potent antiproliferative activities observed against selected cancer cell lines, including multidrug-resistant phenotypes. Among them, compound 29 showed GI50 (50% growth inhibition) values ranging from 0.3 to 0.9 μM against 26 different tumor cell lines and selectivity for one colon (COLO 205) and two melanoma (SK-MEL-5 and UACC-257) cell lines at the TGI (total growth inhibition) level. The mode of action of 29 was predicted by CellMiner bioinformatic analysis and confirmed by biochemical and cell-based experiments to involve inhibition of the DNA replication process, particularly the initiation of replication, and disruption of mitochondrial membrane potential. The present findings suggest this novel madecassic acid derivative may have potential as an anticancer therapeutic lead for both solid and hematological tumors.
- 25 July 2019
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 82 (8) , 2094-2105
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation
A series of novel madecassic acid (1) derivatives was synthesized, and their cytotoxicity was evaluated against the NCI-60 panel of cancer cell lines. Several analogues exhibited broad-spectrum cytotoxic activities over all nine tumor types represented in the panel, with more potent antiproliferative activities observed against selected cancer cell lines, including multidrug-resistant phenotypes. Among them, compound 29 showed GI50 (50% growth inhibition) values ranging from 0.3 to 0.9 μM against 26 different tumor cell lines and selectivity for one colon (COLO 205) and two melanoma (SK-MEL-5 and UACC-257) cell lines at the TGI (total growth inhibition) level. The mode of action of 29 was predicted by CellMiner bioinformatic analysis and confirmed by biochemical and cell-based experiments to involve inhibition of the DNA replication process, particularly the initiation of replication, and disruption of mitochondrial membrane potential. The present findings suggest this novel madecassic acid derivative may have potential as an anticancer therapeutic lead for both solid and hematological tumors.
- Open Access
- 28 September 2018
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 6, 434
Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade Signaling
In the present study, a series of novel madecassic acid derivatives was synthesized and screened against the National Cancer Institute's 60 human cancer cell line panel. Among them, compounds 5, 12, and 17 displayed potent and highly differential antiproliferative activity against 80% of the tumor cells harboring the B-RafV600E mutation within the nanomolar range. Structure-activity analysis revealed that a 5-membered A ring containing an α,β-unsaturated aldehyde substituted at C-23 with a 2-furoyl group seems to be crucial to produce this particular growth inhibition signature. In silico analysis of the cytotoxicity pattern of these compounds identified two highly correlated clinically approved drugs with known B-RafV600E inhibitory activity. Follow-up analysis revealed inhibition of the ERK signaling pathway through the reduction of cellular Raf protein levels is a key mechanism of action of these compounds. In particular, 17 was the most potent compound in suppressing tumor growth of B-RafV600E-mutant cell lines and displayed the highest reduction of Raf protein levels among the tested compounds. Taken together, this study revealed that modifications of madecassic acid structure can provide molecules with potent anticancer activity against cell lines harboring the clinically relevant B-RafV600E mutation, with compound 17 identified as a promising lead for the development of new anticancer drugs.
- 28 September 2018
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 6, 434
Open AccessSynthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade Signaling
In the present study, a series of novel madecassic acid derivatives was synthesized and screened against the National Cancer Institute's 60 human cancer cell line panel. Among them, compounds 5, 12, and 17 displayed potent and highly differential antiproliferative activity against 80% of the tumor cells harboring the B-RafV600E mutation within the nanomolar range. Structure-activity analysis revealed that a 5-membered A ring containing an α,β-unsaturated aldehyde substituted at C-23 with a 2-furoyl group seems to be crucial to produce this particular growth inhibition signature. In silico analysis of the cytotoxicity pattern of these compounds identified two highly correlated clinically approved drugs with known B-RafV600E inhibitory activity. Follow-up analysis revealed inhibition of the ERK signaling pathway through the reduction of cellular Raf protein levels is a key mechanism of action of these compounds. In particular, 17 was the most potent compound in suppressing tumor growth of B-RafV600E-mutant cell lines and displayed the highest reduction of Raf protein levels among the tested compounds. Taken together, this study revealed that modifications of madecassic acid structure can provide molecules with potent anticancer activity against cell lines harboring the clinically relevant B-RafV600E mutation, with compound 17 identified as a promising lead for the development of new anticancer drugs.
- 1 December 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 142, 95-130
Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment
- 1 December 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 142, 95-130
Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment
- 1 January 2014
- Published by Elsevier
- p. 33-73
Highlights of Pentacyclic Triterpenoids in the Cancer Settings
- 1 January 2014
- Published by Elsevier
- p. 33-73
Highlights of Pentacyclic Triterpenoids in the Cancer Settings